Stay updated with breaking news from Track Designation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CBL-514 is the first product to treat cellulite at the raised areas.Currently, there is no effective and safe cellulite treatment on the market. The global market for cellulite treatment is estimated to expand to $7.37 billion in 2034.CBL-0201EFP...
NEW TAIPEI CITY, April 26, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) today announced the topline results of the CBL-0201EFP Phase 2 study,
AB-1002 is being studied for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms
Treatment with LYT-200 is currently being assessed in a phase 1/2 adaptive design trial in advanced/metastatic solid tumors and in a phase 1b clinical trial.
Investegate announcements from FDA Grants PRTC's LYT-200 Fast Track Designation